Skip to content

Study · Systematic review · 2026

5 results

Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.

Chen QX, Zhou XY, Wu Q, Xie JJ, Xu Y, Teng FY, Guo M

Endocrine15 Aug 2026

PMID42603240 (opens in a new tab)DOI10.1007/s12020-026-04757-7 (opens in a new tab)PepBankPUB-42603240
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in type 2 diabetes or obesity, tirzepatide was associated with a lower risk of hypertension-related adverse events.

    In plain wordsIn a pooled analysis of trials in people with type 2 diabetes or obesity, tirzepatide was linked to fewer high blood pressure events.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHypertension-related treatment-emergent adverse events
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.4 ratio
    hypertension-related events

    Source sentences

    Summary
    Tirzepatide was associated with a lower risk of hypertension-related events (RR = 0.40, 95% CI [0.26-0.60]; p < 0.001).
    1 context sentence
    Summary · context
    This meta-analysis of 32 randomized controlled trials (RCTs), enrolling 47,332 participants, revealed distinct differences in the blood pressure-related safety profiles of tirzepatide and semaglutide.
  2. 02HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in type 2 diabetes or obesity, tirzepatide was associated with a higher risk of hypotension-related adverse events.

    In plain wordsIn a pooled analysis of trials in people with type 2 diabetes or obesity, tirzepatide was linked to more low blood pressure events.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHypotension-related treatment-emergent adverse events
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    2.45 ratio
    hypotension-related events

    Source sentences

    Summary
    This potent antihypertensive effect was accompanied by an increased risk of hypotension-related events (RR = 2.45, 95% CI [1.35-4.45]; p = 0.003)
    1 context sentence
    Summary · context
    This meta-analysis of 32 randomized controlled trials (RCTs), enrolling 47,332 participants, revealed distinct differences in the blood pressure-related safety profiles of tirzepatide and semaglutide.
  3. 03HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials, the risk of hypotension-related adverse events with tirzepatide was higher at higher doses.

    In plain wordsIn a pooled analysis of trials, tirzepatide at higher doses was linked to more low blood pressure events.

    Peptide
    Tirzepatide
    Outcome
    IncreaseHypotension-related adverse events at higher doses
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    higher dosesAs given in this study (human).

    Measurements

    RR
    2.58 ratio
    higher doses

    Source sentences

    Summary
    particularly at higher doses (RR = 2.58, 95% CI [1.38-4.81]; p = 0.003).
    1 context sentence
    Summary · context
    This meta-analysis of 32 randomized controlled trials (RCTs), enrolling 47,332 participants, revealed distinct differences in the blood pressure-related safety profiles of tirzepatide and semaglutide.
  4. 04HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in type 2 diabetes or obesity, semaglutide showed no significant association with hypertension-related adverse events.

    In plain wordsIn pooled trials in people with type 2 diabetes or obesity, semaglutide was not linked to more or fewer high blood pressure events.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypertension-related treatment-emergent adverse events
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    0.81 ratio
    hypertension-related events

    Source sentences

    Summary
    Semaglutide exhibited a relatively neutral blood pressure-related safety profile, showing no significant association with either hypertension-related events (RR = 0.81, 95% CI [0.57-1.15]; p = 0.233)
    1 context sentence
    Summary · context
    This meta-analysis of 32 randomized controlled trials (RCTs), enrolling 47,332 participants, revealed distinct differences in the blood pressure-related safety profiles of tirzepatide and semaglutide.
  5. 05HumanSystematic reviewSafety outcome

    In a meta-analysis of randomized trials in type 2 diabetes or obesity, semaglutide showed no significant association with hypotension-related adverse events.

    In plain wordsIn pooled trials in people with type 2 diabetes or obesity, semaglutide was not linked to more or fewer low blood pressure events.

    Peptide
    Semaglutide
    Outcome
    No significant changeHypotension-related treatment-emergent adverse events
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    RR
    1.39 ratio
    hypotension-related events

    Source sentences

    Summary
    Semaglutide exhibited a relatively neutral blood pressure-related safety profile, showing no significant association with either hypertension-related events (RR = 0.81, 95% CI [0.57-1.15]; p = 0.233) or hypotension-related events (RR = 1.39, 95% CI [0.81-2.36]; p = 0.232), although potential protect…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.